clinical trial planning, conduct, and oversight. It ensures compliance with ICH E8(R1), focusing on study quality by integrating risk-based approaches and identifying critical-to-quality (CtQ) factors that safeguard participant safety and data reliability.

Scope

This SOP applies to sponsors, CROs, investigators, QA, clinical operations, and regulatory affairs staff involved in clinical trial design, conduct, monitoring, and reporting. It covers protocol design, risk assessment, quality tolerance limits, documentation, and inspection readiness.

Responsibilities

• Sponsor: Defines CtQ factors, oversees QbD integration, and ensures study quality oversight.
• CRO: Implements QbD processes operationally and provides periodic reports to sponsor.
• Investigator: Ensures site-level adherence to QbD principles.
• QA: Conducts audits to verify QbD implementation.
• Clinical Operations: Monitors trial activities against quality tolerance limits.

Accountability

The Sponsor’s Clinical Quality Head is accountable for ensuring adherence to ICH E8(R1) requirements in trial planning and execution.

Procedure

1. Quality by Design Integration
1.1 Identify critical-to-quality (CtQ) factors based on study objectives.
1.2 Incorporate CtQ into protocol and monitoring plans.
1.3 Record in QbD Planning Log (Annexure-1).

2. Risk Assessment and Mitigation
2.1 Conduct structured risk assessment workshops.
2.2 Define risk indicators and mitigation strategies.
2.3 Document in Risk Assessment Log (Annexure-2).

3. Quality Tolerance Limits (QTLs)
3.1 Establish measurable QTLs for critical data points.
3.2 Monitor deviations and escalate as required.
3.3 Record in QTL Monitoring Log (Annexure-3).

4. Oversight and Monitoring
4.1 Ensure ongoing oversight of QbD processes.
4.2 Monitor adherence during site visits and central monitoring.
4.3 Record in Oversight Log (Annexure-4).

5. Documentation and Archiving
5.1 File QbD documentation in TMF and ISF.
5.2 Ensure inspection readiness for regulatory agencies.
5.3 Document archiving in QbD Documentation Log (Annexure-5).

Abbreviations

• SOP: Standard Operating Procedure
• QbD: Quality by Design
• CtQ: Critical-to-Quality
• ICH: International Council for Harmonisation
• QTL: Quality Tolerance Limits
• CRO: Contract Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. QbD Planning Log (Annexure-1)
2. Risk Assessment Log (Annexure-2)
3. QTL Monitoring Log (Annexure-3)
4. Oversight Log (Annexure-4)
5. QbD Documentation Log (Annexure-5)

References

• ICH E8(R1) – General Considerations for Clinical Studies
• ICH GCP Guidelines
• FDA – Quality by Design in Clinical Development

Version: 1.0

Approval Section

Prepared By	Ravi Kumar, Clinical Quality Manager
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Head Clinical Operations

Annexures

Annexure-1: QbD Planning Log

Date	Protocol ID	CtQ Identified	Prepared By	Status
01/09/2025	QBD-2025-01	Primary Endpoint Reliability	Reg Affairs	Completed

Annexure-2: Risk Assessment Log

Date	Risk Factor	Mitigation Strategy	Prepared By	Status
03/09/2025	High Dropout Rate	Retention Plan	CRO	Monitored

Annexure-3: QTL Monitoring Log

Date	Parameter	QTL Value	Deviation	Status
05/09/2025	Primary Endpoint Data	<5% Missing	2%	Within Limit

Annexure-4: Oversight Log

Date	Oversight Activity	Performed By	Status
07/09/2025	Central Monitoring	Clinical Ops	Compliant

Annexure-5: QbD Documentation Log

Date	Document Type	Filed By	Location	Status
10/09/2025	QbD Risk Assessment	QA	TMF	Archived

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
26/08/2025	00	Initial version	New SOP creation	Head Clinical Operations

For more SOPs visit: Pharma SOP